Gujarat Terce Laboratories Past Earnings Performance
Past criteria checks 3/6
Gujarat Terce Laboratories's earnings have been declining at an average annual rate of -38.3%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 9.4% per year. Gujarat Terce Laboratories's return on equity is 8.5%, and it has net margins of 1%.
Key information
-38.3%
Earnings growth rate
-30.5%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 9.4% |
Return on equity | 8.5% |
Net Margin | 1.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Gujarat Terce Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 487 | 5 | 238 | 0 |
30 Sep 23 | 475 | -2 | 240 | 0 |
30 Jun 23 | 481 | -11 | 239 | 0 |
31 Mar 23 | 468 | -17 | 234 | 0 |
31 Dec 22 | 432 | -41 | 220 | 0 |
30 Sep 22 | 421 | -37 | 207 | 0 |
30 Jun 22 | 396 | -26 | 197 | 0 |
31 Mar 22 | 401 | 9 | 182 | 0 |
31 Dec 21 | 367 | 5 | 165 | 0 |
30 Sep 21 | 331 | 0 | 158 | 0 |
30 Jun 21 | 301 | -5 | 137 | 0 |
31 Mar 21 | 252 | -25 | 142 | 0 |
31 Dec 20 | 286 | -11 | 167 | 0 |
30 Sep 20 | 316 | -7 | 170 | 0 |
30 Jun 20 | 356 | 10 | 177 | 0 |
31 Mar 20 | 375 | 3 | 187 | 0 |
31 Dec 19 | 362 | 12 | 163 | 0 |
30 Sep 19 | 344 | 14 | 161 | 0 |
30 Jun 19 | 312 | -2 | 133 | 0 |
31 Mar 19 | 310 | 4 | 147 | 0 |
31 Dec 18 | 317 | 2 | 150 | 0 |
30 Sep 18 | 311 | 0 | 147 | 0 |
30 Jun 18 | 313 | 10 | 123 | 0 |
31 Mar 18 | 290 | 3 | 140 | 0 |
31 Dec 17 | 257 | -3 | 127 | 0 |
30 Sep 17 | 241 | -3 | 108 | 0 |
30 Jun 17 | 246 | -7 | 107 | 0 |
31 Mar 17 | 253 | 0 | 120 | 0 |
31 Dec 16 | 267 | 11 | 119 | 0 |
30 Sep 16 | 273 | 7 | 125 | 0 |
30 Jun 16 | 249 | -6 | 2 | 0 |
31 Mar 16 | 250 | -7 | 118 | 0 |
31 Dec 15 | 257 | -16 | 147 | 0 |
30 Sep 15 | 251 | -12 | 138 | 0 |
30 Jun 15 | 261 | -9 | 141 | 0 |
31 Mar 15 | 265 | 1 | 119 | 0 |
31 Dec 14 | 303 | 3 | 123 | 0 |
30 Sep 14 | 303 | 2 | 124 | 0 |
30 Jun 14 | 301 | 4 | 114 | 0 |
31 Mar 14 | 288 | 2 | 122 | 0 |
31 Dec 13 | 136 | 1 | 94 | 0 |
30 Sep 13 | 177 | 1 | 94 | 0 |
30 Jun 13 | 226 | 0 | 87 | 0 |
Quality Earnings: 524314 has high quality earnings.
Growing Profit Margin: 524314 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524314 has become profitable over the past 5 years, growing earnings by -38.3% per year.
Accelerating Growth: 524314 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 524314 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 524314's Return on Equity (8.5%) is considered low.